Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPC-64005
- Development stage
- Phase 2
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OPC-64005 is an investigational small molecule drug classified as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a "triple reuptake inhibitor" (TRI). It acts by inhibiting the reuptake of serotonin, norepinephrine (adrenergic), and dopamine, thereby increasing the levels of these neurotransmitters in the brain. The drug is being developed primarily for the treatment of major depressive disorder and was previously investigated for attention deficit hyperactivity disorder (ADHD), though development for ADHD has been discontinued. OPC-64005 is administered orally. The developer and manufacturer is Otsuka Pharmaceutical[1][2][4].
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on OPC-64005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPC-64005.